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Abstract
Background: The Canadian Inherited Metabolic Diseases Research Network (CIMDRN) is a pan-Canadian practice-
based research network of 14 Hereditary Metabolic Disease Treatment Centres and over 50 investigators. CIMDRN
aims to develop evidence to improve health outcomes for children with inherited metabolic diseases (IMD). We
describe the development of our clinical data collection platform, discuss our data quality management plan, and
present the findings to date from our data quality assessment, highlighting key lessons that can serve as a resource
for future clinical research initiatives relating to rare diseases.
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Methods: At participating centres, children born from 2006 to 2015 who were diagnosed with one of 31 targeted
IMD were eligible to participate in CIMDRN’s clinical research stream. For all participants, we collected a minimum
data set that includes information about demographics and diagnosis. For children with five prioritized IMD, we
collected longitudinal data including interventions, clinical outcomes, and indicators of disease management. The
data quality management plan included: design of user-friendly and intuitive clinical data collection forms;
validation measures at point of data entry, designed to minimize data entry errors; regular communications with
each CIMDRN site; and routine review of aggregate data.
Results: As of June 2019, CIMDRN has enrolled 798 participants of whom 764 (96%) have complete minimum data
set information. Results from our data quality assessment revealed that potential data quality issues were related to
interpretation of definitions of some variables, participants who transferred care across institutions, and the
organization of information within the patient charts (e.g., neuropsychological test results). Little information was
missing regarding disease ascertainment and diagnosis (e.g., ascertainment method – 0% missing).
Discussion: Using several data quality management strategies, we have established a comprehensive clinical
database that provides information about care and outcomes for Canadian children affected by IMD. We describe
quality issues and lessons for consideration in future clinical research initiatives for rare diseases, including
accurately accommodating different clinic workflows and balancing comprehensiveness of data collection with
available resources. Integrating data collection within clinical care, leveraging electronic medical records, and
implementing core outcome sets will be essential for achieving sustainability.
Keywords: Inherited metabolic diseases, Observational research, Registry science, Data quality, Database,
Sustainability
Background
Inherited metabolic diseases (IMD) are a group of more
than 1000 genetic disorders that are characterized by
disruptions in at least one biochemical pathway [1, 2].
Although individually rare, the overall global birth
prevalence of IMD has been estimated as 50.9 per 100,
000 live births [3], representing a significant impact on
population health. Advancements such as next gener-
ation sequencing, metabolomics, and newborn screening
have led to earlier detection of IMD, improved under-
standing of the underlying biological mechanism of
disease, and subsequent development of new therapeu-
tics [4, 5]. Because of these advances in care, patients
with IMD have fewer severe sequelae, in turn reducing
disease morbidity and increasing life expectancy [5]. In
recognition of increased life expectancy among IMD pa-
tients, a current priority in IMD research is long-term
follow-up of patients to generate high quality, longitu-
dinal clinical data to evaluate outcomes and inform both
clinical care and public policy [6, 7].
While randomized controlled trials remain the gold
standard for minimizing risk of bias and confounding in
establishing treatment efficacy and evaluating outcomes
[8], it is often not feasible to conduct a high quality clinical
trial in the context of rare diseases due to an inability to
recruit an adequate sample size to achieve adequate statis-
tical power and to address the characteristic clinical het-
erogeneity of many rare diseases. Thus, population-based
cohort studies, patient registries, and practice-based evi-
dence networks are important tools for investigating
natural history, evaluating disease management practices,
establishing effectiveness of interventions, and assessing
both short- and long- term outcomes [9–12]. To success-
fully achieve these goals, collection of high quality obser-
vational data is imperative [13, 14].
In 2012, with funding from a Canadian Institutes of
Health Research Emerging Team grant, the Canadian
Inherited Metabolic Diseases Research Network
(CIMDRN) was established. CIMDRN is a pan-Canadian,
multidisciplinary, practice-based network with the overall
goal of generating high quality observational evidence to
improve care and outcomes for children diagnosed with
IMD in Canada [15]. Over 50 investigators from across
Canada in the fields of pediatric care for IMD patients,
epidemiology, and health services and policy research are
involved, along with 14 Canadian Hereditary Metabolic
Disease Treatment Centres (Fig. 1). CIMDRN’s clinical re-
search stream uses medical chart-abstracted data to: (i)
describe the longitudinal experience of a population-based
cohort of Canadian children diagnosed with IMD; and (ii)
investigate associations between patterns of interventions
and clinical outcomes in this cohort. To achieve these
goals, development of a comprehensive data quality man-
agement plan is critical to the establishment and mainten-
ance of a high-quality clinical database.
Data quality principles established for disease registries
include: completeness, accuracy, interpretability/accessi-
bility, relevance, timeliness, coherence/comparability, and
data protection/privacy [16, 17]. These principles are also
applicable to our longitudinal clinical database, which,
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similar to a research registry, is designed to support mul-
tiple descriptive and evaluative studies. Establishing a set
of quality assurance procedures (activities undertaken in
advance of data collection to ensure the highest quality
outputs), quality control procedures (activities undertaken
during and following data collection to identify and cor-
rect errors), and quality assessment procedures (activities
undertaken to evaluate the quality of the whole system) is
recommended for registries to ensure robust data collec-
tion throughout all research activities [18, 19]. In this
paper, we describe the design and development of our
clinical data collection platform, discuss our data quality
management plan, and present the findings to date from
our data quality assessment, highlighting key lessons that
can serve as a resource for future clinical research initia-
tives relating to rare diseases.
Methods
To ensure high quality clinical data collection, we estab-
lished specific data quality management strategies accord-
ing to best practice guidelines for disease-specific patient
registries [18, 20] and medical chart data abstraction [21,
22]. Procedures were adapted based on consultation with
CIMDRN investigators and experts in database architec-
ture and personal health information privacy.
Developing a clinical data collection platform
We established a working group of over 20 CIMDRN in-
vestigators to advise CIMDRN’s clinical research activ-
ities. This group included care providers at each
CIMDRN centre and investigators with expertise in the
clinical evaluative sciences. Responsibilities of the group
included: refining the list of CIMDRN-targeted IMD;
developing measures of relevant clinical outcomes, inter-
ventions, and intermediate indicators of disease manage-
ment; and establishing procedures for clinical data
collection and implementation at each centre. A list of
31 targeted IMD was developed. We focused on treat-
able diseases that were characterized by important clin-
ical and/or health policy questions. This included many
target disorders of newborn screening, given the need
for long-term follow-up information to better under-
stand natural history and outcomes in a screened popu-
lation (Table 1). To ensure feasibility of data collection
within the resources available, we opted to identify a
subset of five of CIMDRN’s targeted IMD as priority dis-
eases for in-depth longitudinal data collection, based on
preliminary evidence of variability in outcomes and in
clinical management for these diseases (Table 1).
Through consensus of the working group, we established
a framework (Table 2) to guide the development of a set of
data elements with operationalized definitions that would
be collected systematically from participants’ medical
charts. Specific data elements were chosen by the working
group based on their perceived clinical importance and
consideration of whether the information was likely to be
present in participants’ medical record. We also considered
inclusion of data elements from related longitudinal re-
search projects, for example, the Newborn Screening
Translational Research Network (https://www.nbstrn.org/)
[23] and the Urea Cycle Disorders Consortium (https://
www.rarediseasesnetwork.org/cms/ucdc) [24].
Fig. 1 Location of Canadian Hereditary Metabolic Treatment Centres that are participating in CIMDRN (n = 14)
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Quality assurance
Eligibility criteria
The same eligibility criteria were applied across partici-
pating sites. Children were enrolled (with informed,
parental consent and child assent, if applicable) in
CIMDRN’s clinical research stream if they were:
 diagnosed with one of the targeted IMD
 born from 2006 to 2015 (any age for 3 ultra-rare dis-
eases, see Table 1)
 received care at one of 14 participating Canadian
Hereditary Metabolic Disease Treatment Centres
Centralized data collection
Centre staff reviewed participants’ medical records and
securely recorded information in our centralized clinical
database, facilitated by Research Electronic Data Capture
(REDCap) and hosted at the Children’s Hospital of East-
ern Ontario Research Institute. REDCap is a secure,
web-based application that is designed to support data
collection for research studies [25]. At some sites, the
participants’ metabolic clinic information was accessed
via their hospital electronic medical record, while at
other sites without electronic medical record infrastruc-
ture, information was accessed via their paper chart held
within the metabolic clinic. Research staff at each satel-
lite site were given a data entry training session via tele-
conference/webinar by staff at the central coordinating
site and were provided with a comprehensive data entry
manual and frequently-asked-questions document to
guide them through data entry.
Given that staff extracting data from medical charts at
participating centres had differing professional back-
grounds (e.g., dietitians, clinical research coordinators,
fellows/ trainees, research students) and not all were
content experts in the field of IMD, an intuitive and
user-friendly interface (Fig. 2) for data entry was critical
for quality assurance (data collection tools available
upon reasonable request). We organized data fields into
a set of short forms, similar to a series of web surveys,
by type of information collected (i.e., participant charac-
teristics, family/household information, diagnostic la-
boratory investigations, monitoring laboratory tests,
ongoing clinic visits). We also used branching logic to
organize data fields according to the participant’s diag-
nosis (e.g., routine laboratory test options specific to
monitoring medium-chain acyl-CoA dehydrogenase
(MCAD) deficiency are not displayed for a participant
diagnosed with a different IMD).
We designed our clinical data collection forms to limit
the potential for missing data and data entry errors.
When possible, our data fields relied on close-ended re-
sponses (e.g., drop down menus with multiple choice or
check-all-that-apply response options) that included an
“unknown” or “not applicable” option in case that infor-
mation had not been recorded in the chart, or an “other,
please specify” category in case the applicable option
was not readily available. Additionally, for data fields
that were open-ended, we required that any empty fields
be “verified as missing” (i.e., confirmation by the individ-
ual entering data that the information was not recorded
Table 1 CIMDRN-targeted IMD (n = 31); priority diseases (bold)




• Phenylalanine hydroxylase (PAH) deficiency
• Homocystinuria









• N-acetylglutamate synthetase deficiency
• Ornithine transcarbamylase deficiency
Organic acid disorders:
• β-ketothiolase deficiency
• Glutaric acidemia type I
• HMG-CoA lyase deficiency
• Isovaleric academia
• 3-methylcrotonyol-CoA carboxylase deficiency (3MCC)
• Methylmalonic acidemias (MMA)
• Propionic acidemia
Fatty acid oxidation disorders:
• Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency
• Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency
• Carnitine uptake defect (CUD)
• Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
• Trifunctional protein deficiency
Other disorders:
• Guanidinoacetate methyltransferase (GAMT) deficiency*
• Mucopolysaccharidosis type I (MPSI)*
• Farber disease*
• Galactosemia
• Glycogen storage disease type I
• Multiple carboxylase deficiency/biotinidase deficiency
• Pyridoxine-dependent epilepsy
*individuals of any age enrolled if receiving care at a participating Centre
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in the chart); this was facilitated using a built-in data
verification tool in REDCap. REDCap also allows for
some automated validation of data fields (e.g., ensuring
that a recorded value/date is within a pre-defined range
or ensuring that only numeric characters can be entered
in a numeric field). We also set automated calculations
for derived variables, such as body mass index (based on
entered height and weight), to protect against errors in
calculations entered manually.
For all 31 targeted IMD, we collected a minimum set
of data that included information on sociodemographic
characteristics, case ascertainment and diagnosis, and
initial interventions. For children with the five IMD we
prioritized for in-depth longitudinal data collection, we
collected information beyond the diagnostic period,
which was organized around each follow-up visit to the
metabolic clinic. These data included information about
interventions received, clinical outcomes, and indicators
of disease management. Depending on branching logic,
there were between 37 and 63 required data fields for
each disease in the minimum dataset, and between 39
and 68 required data fields at each clinic visit for
Table 2 Framework used to guide the choice and definitions for data elements included in our clinical data collection tool
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Fig. 2 Example data collection form in Research Electronic Data Capture (REDCap) [25]
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longitudinal data collection. Each database also con-
tained several hundred additional data fields that depend
on the specific disease and branching logic options (e.g.,
specific laboratory test results, prescriptions, etc.). To
limit misinterpretation of data fields, we added a defin-
ition developed by the clinical research working group
to each data field and incorporated the definitions into a
data dictionary that was made available to participating
centres through REDCap.
This study was reviewed and approved by the research
ethics board at each participating centre (see
Acknowledgements).
Data privacy/protection
We developed a set of data privacy procedures that were
agreed upon among the participating sites. Specifically,
as described above, all data were collected using
REDCap and are stored within the Children’s Hospital
of Eastern Ontario Research Institute secure server(s).
REDCap uses a 128-bit data encryption and requires a
user ID and password to access [25]. To protect partici-
pant identification and privacy, we generated study-
specific ID numbers for each participant and did not
collect any overtly identifying information within the
clinical research database (a separately partitioned data-
base stores contact information for participants from
selected centres who agree to be contacted to participate
in future research). In addition, CIMDRN investigators
and staff at each satellite site are only able to view clin-
ical data for the participants enrolled at their centre.
Investigators and staff at the central coordinating site
are able to access clinical data for participants across all
sites in order to facilitate centralized quality control ac-
tivities (see below) and conduct analyses. We have devel-
oped a data request policy that allows any CIMDRN
investigator to request de-identified data for participants
across all sites provided their request is approved by
CIMDRN’s Data Advisory Committee. Finally, we do not
publicly report potentially identifying results for any cell
with fewer than five participants contributing data.
Quality control
Communication with satellite sites
Routine communication between CIMDRN’s central of-
fice and each satellite site was a key component for qual-
ity control. Teleconferences were held with the site
coordinators 1–2 times per year to discuss and answer
questions about clinical data collection and other
CIMDRN-related activities. The central office also main-
tained and updated a data entry manual and an elec-
tronic frequently-asked-questions document, accessible
via REDCap. This document included questions and an-
swers reflecting concerns raised by satellite sites as data
collection progressed. A bulletin was also sent from the
central office via e-mail to site coordinators every 2–4
weeks, highlighting any improvements and/or changes
made to the clinical database (e.g., addition/removal of
data fields). The CIMDRN central office also regularly
issued individual status reports to each of the sites,
which provided specific feedback to each centre about
their data entry progress and highlighted any potential
data quality issues noted by the central office. Finally,
site coordinators were encouraged to contact the central
office with any questions or concerns about data collec-
tion. Central site staff responded within 1–3 days and ar-
ranged telephone or webinar support as appropriate. In
response to feedback received from our satellite sites, we
occasionally made improvements to our data collection
forms, and maintained a change management log to
track these changes.
Centralized data verification
Each participant’s data were subject to centralized verifi-
cation using REDCap-enabled correspondence between
the central office and each satellite site to address spe-
cific concerns. See Table 3 for an overview of items that
were checked as part of this verification process. Once
the central office was satisfied that data had been en-
tered correctly for a given participating individual, the
data collection forms for that individual were marked as
‘verified’, locked to prevent any changes without ap-
proval by the central site, and associated data were con-
sidered useable for analysis.
Data quality assessment
The central office also conducted routine monitoring of
aggregate data (descriptive analysis) to identify the fre-
quency of item-missing data, both overall and by centre,
and to identify systematic differences in data elements
across centres. When we identified systematic differ-
ences or unusual data patterns, we followed up with
Table 3 Data validation items developed by the central
CIMDRN office
Items verified
• Check that blank data fields are confirmed as intentionally blank to
indicate that information is not available in the participant’s chart
• Check that any dates that are entered occur within a reasonable
time frame (e.g., dates should not occur in the future)
• Check that participant data are recorded in chronological order
• Follow up with centre regarding any extreme values that could
represent a data entry error
• Check to ensure correct organization of information (i.e., data
entered in correct data field and in the correct format)
• Check that organization of data in clinical database follows
expected workflow at that centre (i.e., order of events is reasonable
and appropriate)
• Ensure appropriate unit conversion, if applicable
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centre staff to determine whether data fields had been
correctly interpreted and whether there were circum-
stances at a centre (e.g., charting practices) that may
have compromised the availability or quality of data. We
also communicated preliminary descriptive findings
from participants enrolled across sites to clinical investi-
gators in the network, to discuss potential sources of
variation, which may reflect real differences in practice
or data quality. Below are the results from our data qual-
ity assessment to date, including the proportion of data
entry that is complete, frequency of missing data, and
discussion of other potential data quality issues that
were identified during our assessment.
Results
Data entry
We have enrolled 798 children in CIMDRN, of whom
412 (52%) have been diagnosed with one of the five dis-
eases prioritized for longitudinal data collection. Data
entry (minimum and longitudinal datasets) is underway
or complete at 13 of the participating centres (one
centre has yet to begin patient enrollment). Of the 798
participants currently enrolled in CIMDRN, 764 (96%)
have complete minimum dataset information recorded
in the clinical database (Fig. 3). Among the 412
participants diagnosed with a priority disease, 299 (73%)
have complete longitudinal follow-up data recorded in
the clinical database (Fig. 3).
Data quality assessment
To date (September 24, 2019), our data quality assess-
ment has prioritized the minimum dataset (sociodemo-
graphic information, ascertainment and diagnosis
information) for all CIMDRN-targeted IMD and the lon-
gitudinal dataset information (interventions received,
clinical outcomes, indicators of disease management) for
phenylalanine hydroxylase (PAH) deficiency.
Item-missing data
As expected, among the 743 participants with complete
minimum dataset information, missing data were com-
mon for many sociodemographic variables due to infor-
mation not being reported in participants’ medical
charts at some or all centres. For example, guardian’s
employment status was missing for over 50% of partici-
pants, and number of people living in a participant’s pri-
mary household was missing for 27% of participants.
Little to no information was missing regarding disease
ascertainment (e.g., by newborn screening, clinical symp-
toms, and/or family history – 0% missing) and diagnostic
Fig. 3 CIMDRN participant flow diagram as of September 24, 2019
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timelines (9% missing diagnosis date/age, 9% missing
newborn screen positive date, Table 4). For diagnostic
tests considered universally important, little information
was missing from participants’ medical charts (Table 4).
In cases where important information regarding ascer-
tainment and diagnosis appeared to be missing, we con-
tacted the research staff at the corresponding site to try
to determine the specific reasons for these missing data.
In many of these cases, missing information was due to
participants moving or transferring care. For example,
13 of 127 participants diagnosed with MCAD deficiency
(10%) did not have an acylcarnitine profile recorded in
the diagnostic test data available to CIMDRN (Table 4).
We have determined that among these 13 participants,
most were not diagnosed at their consenting centre and
did not have diagnostic test results transferred to their
current centre. Other reasons for missing data on this
variable included early mortality and diagnosis con-
firmed by testing for a familial mutation.
Missing data were, at times, related to the organization
of patient charts. For example, while 113 individual
neuropsychological assessments were recorded among
22 PAH deficiency participants, only 84 (74%) of those
assessments were accompanied by test results in partici-
pants’ main hospital charts (i.e., in the other cases, the
chart indicated that the test was ordered or completed,
but the test-specific results were not present). For ex-
ample, at one centre, 100% of the neuropsychological
tests recorded in our database have accompanying re-
sults, compared to 37% of those for participants from
another centre. Upon further investigation, we learned
that at some centres, neuropsychological test results are
not routinely filed into the patient’s main hospital chart
accessible at the metabolic clinic and therefore for data
entry for our cohort.
Other data quality issues
During the design phase, we recognized that participants
may move among participating treatment centres during
the study period and, consequently, may be enrolled at
more than one centre. We added a variable to our data-
base about previous receipt of care at another centre
and have proactively reviewed participants’ date of birth
and diagnosed IMD to ensure that potential duplicate
participants would be identified. If a participant was
identified as a potential duplicate, we contacted the ap-
propriate treatment centres to confirm. Using this strat-
egy, we have identified three participants who were
enrolled at more than one centre and we can link their
clinical data as appropriate for specific analyses.
Identification of extreme values via routine descriptive
analyses has also prompted further evaluation of some
participants’ individual data. As an example, age at diag-
nosis for participants with PAH deficiency initially
ranged from 2 to > 200 days, which led to a detailed re-
view of the data for participants diagnosed beyond the
first month of life to ensure the accuracy of data. Upon
further investigation, we determined that differing inter-
pretations of the definition for age at diagnosis (i.e.,
“date upon which investigation results confirming the
Table 4 Missing data for select ascertainment and diagnosis among participants with complete minimum dataset information (n =
764)
IMD Ascertainment and diagnostic workup variables % missing
Across all CIMDRN-targeted diseases Ascertainment method (e.g., by NBS, family history, etc.) 0%
Number of visits to metabolic clinic to determine diagnosis 9%
Age at diagnosis 9%
Centre where diagnosis was established 0%
For those not ascertained by NBS (n = 138), was a NBS test done?a 50%
For those ascertained by NBS (n = 626), was the NBS test positive for the diagnosed disease?a 1%
For those whose NBS test was positive (n = 620), date of NBS test positive/referrala 9%
For those diagnosed symptomatically (n = 125), age at first symptoma 17%
For those diagnosed symptomatically (n = 125), presenting symptomsa 0%
Diagnostic tests considered
universally important
PAH deficiency (n = 215) Plasma amino acid profile 2%
MCAD deficiency (n = 127) Acylcarnitine profile 10%
VLCAD deficiency (n = 33) Acylcarnitine profile < 10%
MPS type I (n = 18) α-L-iduronidase activity < 10%
IMD inherited metabolic disease, NBS newborn screening, PAH phenylalanine hydroxylase, MCAD medium-chain acyl CoA dehydrogenase, VLCAD very long-chain
acyl-CoA dehydrogenase, MPS mucopolysaccharidosis
adenominators for these data elements vary as not all variables were applicable to every participant
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diagnosis become available”) among the treatment cen-
tres were contributing to the inconsistencies. In particu-
lar, some treatment centres assigned a definitive
diagnosis based on test results that take longer to per-
form (e.g., molecular genetic testing) than others (e.g.,
plasma amino acid profile) and yet the corresponding
participants were fully treated under a presumptive diag-
nosis while waiting for these final test results. Similarly,
clarification about definitions for other variables (e.g.,
date of a positive newborn screening test referral, modi-
fied medical foods, clinic visit) have been necessary in
response to queries or due to systematic variation across
centres. For example, one participating centre routinely
conducts a second newborn screening test as part of
their diagnostic workup for some patients, prompting
clarification about which date to use as the newborn
screen positive referral date. For some centres, telemedi-
cine is commonly used to provide care to patients living
in rural or remote areas of Canada so further explan-
ation about the definition of a clinic visit was necessary
to ensure that telemedicine information was being cap-
tured appropriately in our clinical database. To ensure
the reliability of results generated from our clinical data
analyses, we have chosen to minimize the use of vari-
ables for which we have determined inconsistent inter-
pretations among participating centres in our analyses.




Reliable clinical data collection is crucial in generating
robust evidence about the natural history, management
strategies, and clinical intervention effectiveness for
IMD. Incomplete and/or inaccurate data collection com-
promises the interpretation of results; therefore, it is im-
portant to have methods in place to identify and
mitigate any potential issues with data completeness or
accuracy [19, 20]. Throughout the design, implementa-
tion, and maintenance of our clinical data collection
platform, we have learned several lessons that can serve
as a resource for future clinical research initiatives relat-
ing to rare diseases. Consideration of these issues is im-
portant for the long-term sustainability of in-depth,
longitudinal clinical data collection initiatives such as
ours.
Lesson learned #1: mitigating potential data quality issues
relies on good communication with participating sites and
centralized data validation measures
One of the main factors contributing to our success has
been maintaining close communication between the sat-
ellite sites and the central team. With a relatively small
number of participants, we were able to directly
correspond with research staff at each centre to resolve
many data quality issues and improve the quality of our
data virtually in real-time, as the data were entered.
Comparable rare disease initiatives have reported using
similar strategies, such as having a central coordinating
office monitoring data collection and regularly querying
participating satellite sites when data entry errors are
suspected [26, 27]. In addition, engaging with clinician
investigators when reporting preliminary findings helped
to distinguish potential data quality issues from areas
where there is true practice variation. The research staff
who abstracted data from patient charts at most centres
had expertise or familiarity with IMD patient care, which
further helped by minimizing the potential for misinter-
pretation of information.
We have also been successful in mitigating potential
data quality issues, including item-missing data, by using
a variety of centralized data validation measures. Built-in
automatic data validation and centralized manual data
verification were both important for the maintenance of
data collection and have also been reported by others as
strategies for avoiding data entry errors [26–28]. We did
not formally assess inter-rater reliability with respect to
data entry at each site because of limited resources; fu-
ture endeavours should consider building such reliability
assessments into the data quality plan.
Lesson learned #2: to limit misinterpretation of data
elements during data collection, data collection tools must
accommodate different clinic workflows and provide clear
definitions for each data element. The use/analysis of data
elements with known inconsistencies in their interpretation
should be limited
Despite efforts to ensure from the outset that our clin-
ical data collection platform could be easily translated
across treatment centres, challenges remained in accur-
ately accommodating differences in workflow or charting
practices. For example, the type of information and the
level of detail captured within participants’ metabolic
medical record was not always consistent among centres.
In response, we added new data elements or modified
existing data elements as needed (e.g., adding telemedi-
cine variables to account for diet changes that occur
over the phone or by email between participants and
their dietician, adding more response options for labora-
tory locations). With incremental enrollment and data
entry over time, making these post hoc changes to our
database while ensuring consistency with previously-
entered data was relatively straightforward, although it
required a commitment at the satellite centres to occa-
sionally re-visit patient charts and make changes for
consistency. Similarly, we have noted different interpre-
tations of specific data fields among centres despite at-
tempts to provide a clear and comprehensive definition
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for each data element (e.g., modified medical food).
Where possible, we have further clarified these defini-
tions either directly in the database and accompanying
data dictionary or through communications with partici-
pating centres, and have highlighted and corrected po-
tential erroneous data.
Lessons learned #3: ensure that data collection is feasible
among participating sites by balancing volume of data
being recorded with available resources
Developing, implementing, and maintaining a multi-
centre, clinical data collection platform is resource-
intensive. Balancing comprehensiveness and feasibility of
data collection was difficult. This is especially true in the
context of rare diseases where there is often substantial
uncertainty around which elements of patient care are
most important to collect. We sought to be exhaustive
in our data collection effort and record hundreds of data
elements per participant; however, this likely impacted
the timeliness of data collection among the satellite sites
and may have compromised the completeness of our
dataset.
Lessons learned 4: ensure that each participating site’s
information system will be compatible with chosen data
collection system/software
Limitations with the information technology infrastruc-
ture across centres also impacted the timeliness of data
collection. For example, some institutions faced difficulty
with the compatibility and operation of REDCap on their
hospital information system. The initial version of RED-
Cap had slow loading times for the database because of
the large number of data elements in our project; how-
ever, an update to the REDCap software and some
reorganization of our clinical data to lessen the amount
of data being loaded per page resolved this within sev-
eral weeks.
Sustainability
Similar to a research registry, our clinical data collection
platform was designed to support multiple descriptive
and evaluative studies. While we have successfully en-
rolled nearly 800 participants in our cohort and have
collected a comprehensive set of clinical data, sustain-
ability of this initiative is challenged by the intensity of
resources required. Towards developing a more sustain-
able strategy for long-term clinical data collection for
pediatric IMD in Canada, we are currently developing a
strategy to evolve our clinical database into a high qual-
ity disease registry that may be used as a platform to
launch registry-based randomized trials [29, 30], as well
as contribute to better understanding the natural history
of targeted IMD [20]. Developing a disease registry
whose purpose is to collect high quality data to support
on-going descriptive and evaluative studies offers several
advantages in the context of rare diseases, including: i)
improved efficiency for recruiting participants into other
studies; ii) increased external validity of study results as
inclusion criteria are typically broad; iii) opportunity to
answer questions regarding comparative effectiveness of
interventions in real-world settings; and iv) potential to
collect data and better understand long-term outcomes.
In order to achieve the goal of a sustainable disease
registry, we will need to streamline our data collection.
The use of core outcome sets [31] and/or integration
with electronic medical records could facilitate high
quality data collection into a disease registry. Addition-
ally, the use of standardized vocabulary, such as the Hu-
man Phenotype Ontology [32], for data elements would
improve the interoperability with other registries/data
sources [19].
Conclusions
Successfully establishing and maintaining a clinical data
collection platform for a population-based cohort of
children affected by IMD has been both exciting and
challenging. The data collected as part of CIMDRN’s
clinical research stream is ideally suited for better under-
standing natural history of the targeted IMD, evaluating
disease management practices, establishing effectiveness
of interventions, and assessing both short- and long-
term outcomes. The experiences from this project will
be used as scaffolding toward a more sustainable strategy
for long-term clinical data collection for pediatric IMD
in Canada via development of a high quality disease
registry. Integrating data collection within clinical care,
leveraging electronic medical records, and implementing
core outcome sets will be essential for achieving
sustainability.
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